Next Article in Journal
The Role of Perinatal Complications in Neurodevelopmental Outcomes of ART-Conceived Children: Prognostic Model for Brain Immaturity
Previous Article in Journal
The Optimal Type and Dose of Exercise Interventions on VEGF Levels in Healthy Individuals, as Well as Obesity and Chronic Disease Populations: A Network Meta-Analysis
Previous Article in Special Issue
Pathway to Remission in Severe Asthma: Clinical Effectiveness and Key Predictors of Success with Benralizumab Therapy: A Real-Life Study
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Damiański et al. Pathway to Remission in Severe Asthma: Clinical Effectiveness and Key Predictors of Success with Benralizumab Therapy: A Real-Life Study. Biomedicines 2025, 13, 887

1
Clinical Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, 90-419 Lodz, Poland
2
Department of Pneumology, Medical University of Lodz, 90-419 Lodz, Poland
3
Center for Allergy Research, Karolinska Institutet, SE-171 77 Stockholm, Sweden
*
Author to whom correspondence should be addressed.
Biomedicines 2025, 13(10), 2549; https://doi.org/10.3390/biomedicines13102549
Submission received: 17 September 2025 / Accepted: 22 September 2025 / Published: 20 October 2025

Error in Figure

In the original publication [1], there was a mistake in Figure 1b as published. In the section of the figure corresponding to ACQ < 1.5, the values are currently presented incorrectly. According to the text above the figure, the correct values should be “achieved: 33%”, “not achieved: 67%”.
The corrected Figure 1b appears below:
Figure 1. Panel (a) presents the proportion of patients meeting the criteria for clinical remission, clinical response, or classified as non-responders (%). Panel (b) illustrates the individual components of the disease remission criteria after one year of BENRA therapy (expressed as %).
Figure 1. Panel (a) presents the proportion of patients meeting the criteria for clinical remission, clinical response, or classified as non-responders (%). Panel (b) illustrates the individual components of the disease remission criteria after one year of BENRA therapy (expressed as %).
Biomedicines 13 02549 g001
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Damiański, P.; Białas, A.J.; Kołacińska-Flont, M.; Elgalal, A.; Jarmakowska, K.; Kierszniewska, D.; Panek, M.; Kardas, G.; Kuna, P.; Kupczyk, M. Pathway to Remission in Severe Asthma: Clinical Effectiveness and Key Predictors of Success with Benralizumab Therapy: A Real-Life Study. Biomedicines 2025, 13, 887. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Damiański, P.; Białas, A.J.; Kołacińska-Flont, M.; Elgalal, A.; Jarmakowska, K.; Kierszniewska, D.; Panek, M.; Kardas, G.; Kuna, P.; Kupczyk, M. Correction: Damiański et al. Pathway to Remission in Severe Asthma: Clinical Effectiveness and Key Predictors of Success with Benralizumab Therapy: A Real-Life Study. Biomedicines 2025, 13, 887. Biomedicines 2025, 13, 2549. https://doi.org/10.3390/biomedicines13102549

AMA Style

Damiański P, Białas AJ, Kołacińska-Flont M, Elgalal A, Jarmakowska K, Kierszniewska D, Panek M, Kardas G, Kuna P, Kupczyk M. Correction: Damiański et al. Pathway to Remission in Severe Asthma: Clinical Effectiveness and Key Predictors of Success with Benralizumab Therapy: A Real-Life Study. Biomedicines 2025, 13, 887. Biomedicines. 2025; 13(10):2549. https://doi.org/10.3390/biomedicines13102549

Chicago/Turabian Style

Damiański, Piotr, Adam Jerzy Białas, Marta Kołacińska-Flont, Anna Elgalal, Katarzyna Jarmakowska, Dorota Kierszniewska, Michał Panek, Grzegorz Kardas, Piotr Kuna, and Maciej Kupczyk. 2025. "Correction: Damiański et al. Pathway to Remission in Severe Asthma: Clinical Effectiveness and Key Predictors of Success with Benralizumab Therapy: A Real-Life Study. Biomedicines 2025, 13, 887" Biomedicines 13, no. 10: 2549. https://doi.org/10.3390/biomedicines13102549

APA Style

Damiański, P., Białas, A. J., Kołacińska-Flont, M., Elgalal, A., Jarmakowska, K., Kierszniewska, D., Panek, M., Kardas, G., Kuna, P., & Kupczyk, M. (2025). Correction: Damiański et al. Pathway to Remission in Severe Asthma: Clinical Effectiveness and Key Predictors of Success with Benralizumab Therapy: A Real-Life Study. Biomedicines 2025, 13, 887. Biomedicines, 13(10), 2549. https://doi.org/10.3390/biomedicines13102549

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop